Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial.

Ramírez-Amador, V; Esquivel-Pedraza, L; Lozada-Nur, F; De la Rosa-García, E; Volkow-Fernández, P; Súchil-Bernal, L; Mohar, A

Ramírez-Amador, V; Esquivel-Pedraza, L; Lozada-Nur, F; De la Rosa-García, E; Volkow-Fernández, P; Súchil-Bernal, L; Mohar, A.

Affiliation

Ramírez-Amador V; Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, 04960 Mexico City, Mexico. rava1863@cueyatl.uam.mx

Oral Oncol ; 38(5): 460-7, 2002 Jul.

Article in En | MEDLINE | ID: mdl-12110340

Subject(s)

Antineoplastic Agents, Phytogenic/therapeutic use; Mouth Neoplasms/drug therapy; Sarcoma, Kaposi/drug therapy; Sclerosing Solutions/therapeutic use; Sodium Tetradecyl Sulfate/therapeutic use; Vinblastine/therapeutic use; Adult; Double-Blind Method; Follow-Up Studies; HIV Infections/complications; Humans; Injections, Intralesional; Male; Middle Aged; Mouth Neoplasms/complications; Sarcoma, Kaposi/complications; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Sarcoma, Kaposi / Sclerosing Solutions / Sodium Tetradecyl Sulfate / Vinblastine / Mouth Neoplasms / Antineoplastic Agents, Phytogenic Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans / Male / Middle aged Language: En Journal: Oral Oncol Year: 2002 Document type: Article

Search on Google

XML

PubMed Links